{
  "docId": "019de076-e431-717d-85d5-60fbb8c86744",
  "docSlug": "9614dd2dbfdf83d72e770ebfe5753af3",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 37,
  "pageCount": 42,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "why_now",
  "function": "argue_timing",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a comparative structure to contrast the 2L+ (salvage) and 1L (frontline) market opportunities.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-e431-717d-85d5-60fbb8c86744/37",
  "deckHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744",
  "deckJsonHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json",
  "deckAnchorHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-37",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.3,
        "x": 0.17,
        "y": 0.28
      },
      "kind": "list",
      "text": "2L+ No clear standard of care (SOC); ~40% ROS1 G2032R mutation; ~30-55% CNS disease",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22e2c4a6-abdf-4db3-954e-83915966a3e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.3,
        "x": 0.53,
        "y": 0.28
      },
      "kind": "list",
      "text": "1L Current SOC: Crizotinib; ROS1: ~1-3% of NSCLC; ~20-40% CNS disease",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "233cf76e-f83e-44b0-9c98-a01c4d697c27",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.53,
        "y": 0.52
      },
      "kind": "list",
      "text": "Potential to address combined medical needs: ROS1 mutation coverage + CNS activity + avoiding off-target adverse events; Opportunity to drive deep, durable responses; Favorable preliminary safety profile",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e133fe5-aaa6-4de9-82bc-5913ab68086f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.17,
        "y": 0.52
      },
      "kind": "list",
      "text": "Clinical activity observed in heavily pretreated patients with ROS1+ NSCLC: Who likely exhausted all available therapies (ORR: 50%); With ROS1 resistance mutations (ORR: 78%); With history of CNS metastasis (ORR: 73%)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb4e4dc5-d11a-41be-b396-101366b2c970",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.3,
        "x": 0.17,
        "y": 0.44
      },
      "kind": "paragraph",
      "text": "Demonstrated activity where current available therapies have failed",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44fa7a78-cbe4-4587-b0d3-f6a9a3879953",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.3,
        "x": 0.53,
        "y": 0.44
      },
      "kind": "paragraph",
      "text": "Opportunity to supplant standard of care with a differentiated profile",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "956e9f7e-3984-47b5-83f5-9db528ab0c9f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.058,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "Sources: Cortellis Sales and Forecasts, accessed November 2023; Lin et al., J Thorac Oncol 2017; Gainor et al, JCO Precision Oncol 2017; Ou and Zhu Lung Cancer 2019; Patil et al, JTO 2018; Drilon A. et al., EORTC-NCI-AACR 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2f9243f-c4ad-4db0-b081-4deb967f6f43",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.75,
        "x": 0.058,
        "y": 0.19
      },
      "kind": "title",
      "text": "Opportunity to both move up the treatment paradigm & grow the market with deep, durable responses",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c923db50-d5a8-42d2-b744-ad5e6f494d76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.42,
        "x": 0.058,
        "y": 0.118
      },
      "kind": "title",
      "text": "Potential Best-in-class Profile for ROS1+ NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22a4bcd9-1ca2-4450-af8e-0daa4046cc3b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "1261e3d6-b1ce-454d-994b-9b061ef15ada",
      "evidence": "list/bullet: Clinical activity observed in heavily pretreated patients with ROS1+ NSCLC: Who likely exhausted all available therapies (ORR: 50%); With ROS1 resistance mutations (ORR: 78%); With history of CNS metastasis",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}